Basic Study
Copyright ©The Author(s) 2020.
World J Psychiatr. Jul 19, 2020; 10(7): 150-161
Published online Jul 19, 2020. doi: 10.5498/wjp.v10.i7.150
Figure 1
Figure 1 Experimental protocols. Three administration modes were used in this study, including intravitreal injection, intraperitoneal injection and immersion. All resveratrol treatments were carried out 1 d before N-Methyl-D-aspartic acid (NMDA) treatment. Behavior records began immediately after NMDA and MK-801 treatment, which lasted for 1 h. NMDA: N-Methyl-D-aspartic acid; I.V.: Intravitreal injection; I.P.: Intraperitoneal injection; I.M.: Immersion.
Figure 2
Figure 2 Intravitreal injection of N-Methyl-D-aspartic acid causes acute seizure-like behavior in zebrafish. Seizure activity and onset scores following N-Methyl-D-aspartic acid (NMDA)-intravitreal injection (0.1 mol/L and 0.5 mol/L, 50 mg/L resveratrol + 0.5 mol/L NMDA, and 50 mmol/L MK-801 + 0.5 mol/L NMDA). A: The mean seizure scores (± SE) for each treatment group plotted against time after NMDA injection; B: The latency of seizure onset after NMDA injection. Bars represent mean ± SE of the time lag to the onset of the first convulsion in each group. Data were analyzed using one-way ANOVA and t-test for the different groups (n = 6) (bP < 0.01 vs control). NMDA: N-Methyl-D-aspartic acid; RES: Resveratrol; MK: MK-801.
Figure 3
Figure 3 Intraperitoneal injection of N-Methyl-D-aspartic acid causes acute seizure-like behavior in zebrafish. Seizure activity scores and onset times following N-Methyl-D-aspartic acid (NMDA)-intraperitoneal injection (8 and 16 mg/kg, 50 mg/L resveratrol + 16 mg/kg NMDA, and 3 mg/kg MK-801 + 16 mg/kg NMDA). A: The mean seizure scores (± SE) for each group plotted against time after NMDA injection; B: The latency of seizure onset after NMDA injection. Bars represent mean ± SE of the time lag to the onset of the first convulsion in each group. Data were analyzed using one-way ANOVA and t-test for the different groups (n = 6) (bP < 0.01 vs control). NMDA: N-Methyl-D-aspartic acid; RES: Resveratrol; MK: MK-801.
Figure 4
Figure 4 Immersion of N-Methyl-D-aspartic acid causes persistent seizure-like behavior in zebrafish. Seizure activity scores and onset times following N-Methyl-D-aspartic acid (NMDA)-immersion (300 μmol/L and 500 μmol/L NMDA, 40 mg/L resveratrol + 500 μmol/L NMDA, and 3 mg/kg MK-801 + 500 μmol/L NMDA). A: The mean seizure scores (± SE) for each group plotted against time after NMDA immersion; B: The latency of seizure onset after NMDA immersion. Bars represent mean ± SE of the time lag to the onset of the first convulsion in each group. Data were analyzed using one-way ANOVA and t-test for the different groups (n = 6) (aP < 0.05, bP < 0.01 vs control). NMDA: N-Methyl-D-aspartic acid; RES: Resveratrol; MK: MK-801.
Figure 5
Figure 5 Comparison of the three administration routes on seizure score and onset time. Seizure activity scores and onset times following intravitreal injection, intraperitoneal injection and immersion with 0.5 mol/L, 16 mg/kg and 500 μmol/L N-Methyl-D-aspartic acid (NMDA), respectively. A: The mean seizure scores (± SE) for each route plotted against time after NMDA treatment; B: The latency of seizure onset after NMDA treatment. Bars represent mean ± SE of the time lag to the onset of the first convulsion using each method. Data were analyzed using one-way ANOVA and t-test for the different routes (n = 6) (aP < 0.05). NMDA: N-Methyl-D-aspartic acid; I.V.: Intravitreal injection; I.P.: Intraperitoneal injection; I.M.: Immersion.